Athira Pharma Raises $90M as Bothell Firm Shifts Focus to Breast Cancer

Athira Pharma is raising $90M through a private placement as it shifts its primary focus to breast cancer. The funding accompanies a licensing deal with Sermonix Pharmaceuticals for lasofoxifene, a Phase 3 metastatic breast cancer drug. The capital will support development through anticipated mid-2027 data and into 2028, while Athira continues advancing its ALS program.